摘要:
The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N--[4-methyl-3-( 4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
摘要:
The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-pheny]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
摘要:
The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
摘要:
The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of lmatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
摘要:
The present invention relates to nanoparticulate compositions in which the active agent is a topoisomerase I inhibitor and pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer.
摘要:
A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.
摘要:
The invention relates to formulations of agrochemical compounds formulated as water emulsifiable granules and combined with boron containing fertilisers in the spray tank, to a process for the production of such formulations and to their use as novel, advantageous formulations of crop protection agents.
摘要:
A magnetic rail brake, particularly an eddy current brake for rail vehicles, has at least one exciter coil which comprises a coil around a pole core as well as a device for holding the coil and/or for the protection against outside environmental influences. The pole core and/or protection device are composed of individual components which are at least largely electrically insulated with respect to one another.
摘要:
A new process for preventing the crystallization of certain azole derivatives in the spray equipment upon spraying mixtures containingA) certain azole derivatives which have a tendency to crystallize andB) if appropriate one or more other active compounds and additives,which process comprises adding at least one phosphoric ester of the formula ##STR1## in which R.sup.1 represents alkyl having 2 to 18 carbon atoms andR.sup.2 and R.sup.3 independently of one another represent alkyl having 2 to 12 carbon atoms,to the spray mixture before spraying.
摘要:
The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (I) with salicylic acid, and also to processes for preparation thereof and use thereof.